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“Real international collaboration only began when electrical telegraphy became an important instrument of communication. 
Again, as in the case of the visual telegraph, at first there were only national networks...whenever a line reached a national 
frontier, there it ceased. This was as much due to the different systems employed, each having its own code vocabulary...” 
ITU-T Report: 50 Years of Excellence (20/07/2006) [http://www.itu.int/ITU-T/] 
 
In the management of biomedical data, vocabularies such as ontologies and terminologies (O/Ts) are used for (i) domain 
knowledge representation and (ii) interoperability. The knowledge representation role supports the automated reasoning 
on, and analysis of, data annotated with O/Ts.  At an interoperability level, the use of a communal vocabulary standard for a 
particular domain is essential for large data repositories and information management systems to communicate consistently 
with one other. Consequently, the interoperability benefit of selecting a particular O/T as a standard for data exchange 
purposes is often seen by the end-user as a function of the number of applications using that vocabulary (and, by extension, 
the size of the user base). Furthermore, the adoption of an O/T as an interoperability standard requires confidence in its 
stability and guaranteed continuity as a resource.  
 
Unregulated practices in vocabulary development and deployment impact the interoperability benefit of biomedical 
vocabularies, for example: 
i. In biological research, new O/Ts are typically developed to improve the knowledge representation capabilities for a 
particular domain of study. While competition among an increasing number of overlapping vocabularies stimulates 
further creative development in the field, the uncoordinated adoption of different O/Ts for the same domain also 
erodes into their collective interoperability benefit. 
ii. While scientific groups are becoming increasingly familiar with tools and techniques to create vocabularies, few are 
prepared for the level of resource commitment and community engagement required to sustain the (i) 
dissemination of their work to improve the interoperability benefit, (ii) maintenance of their vocabulary in a robust 
(and backwards-compatible) manner, (ii) adoption of the vocabulary by the community, (iii) provision of support to 
user feedback and feature requests, and (iv) co-ordination of development with complementary vocabularies in 
neighbouring domains. 
iii. Different vocabulary licensing conditions offered to academic, clinical and industry users may affect the universal 
adoption of O/Ts. For example, such restrictions may interfere with community-wide interoperability operations 
involving O/Ts that are not licensed for public use. 
 
The presence of multiple overlapping O/Ts represents one aspect of the interoperability problem. At the other extreme is, of 
course, the complete lack of: 
iv. viable O/Ts to satisfy the demand in a particular field,  
v. awareness of the O/T benefits,  
vi. well-defined data structures that provide a proper context for O/T terms (term context is crucial in electronic 
health records as it allows entries to be linked chronologically as a means to trace the evolution of a patient’s 
health status), as well as 
vii. a validated business model that motivates and rewards O/T adoption. 
 
Achieving widespread semantic interoperability in key areas such as healthcare is a complex task1
1. The Open Biomedical Ontology Foundry initiative that is driven by the knowledge representation and 
interoperability needs of a wide spectrum of the biological community in an effort to co-ordinate the coherent 
development and quality control of interoperable ontologies [
. In view of the central role 
O/Ts play in the development of electronic health record (EHR) interoperability standards, the ELSA effort should invest in 
the active governance of biomedically-relevant vocabularies in order to assist with the challenges (i. to vii.) listed above. In 
particular, ELSA should seek to support research into a biomedical semantic interoperability standards development body 
that draws upon the following examples: 
http://www.obofoundry.org/]; 
2. ISO/IEEE/CEN 11073 Health Informatics Committee for the joint standards addressing the interoperability of 
medical devices [http://grouper.ieee.org/groups/detailed_index.html - EMB:11073]; 
                                                            
1 See: http://ec.europa.eu/information_society/activities/health/docs/publications/2009/2009semantic-health-report.pdf 
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3. ISO/EN 13606 Electronic Health Record Communication standard which defines models and interfaces for EHR 
interoperability and formal approaches for systematising clinical data structures 
[http://www.iso.org/iso/catalogue_detail.htm?csnumber=40784]; 
4. EMEA's Committee for Medicinal Products for Human Use (CHMP). This committee approves scientific advice given 
on the drug development process, as well as assessing whether a medicinal product has a positive risk benefit for a 
given indication (e.g. a disease state). Furthermore it prepares EMEA’s opinion for the EC’s marketing authorisation 
(initially for a fixed period of time) for a new product, as well as assessing significant modifications through the 
lifecycle of a product. It also issues expert guidelines on the investigational approach to drug development in 
particular disease states [http://www.emea.europa.eu/htms/general/contacts/CHMP/CHMP.html]. 
 
The ELSA initiative should therefore address directly challenges i. to vii. through a study of methodologies that are relevant 
to a body that supports the development of O/T-based semantic interoperability standards by: 
1) Advising on funding priorities for new vocabularies (e.g. target indications (domains), knowledge representation 
requirements); 
2) Issuing guidelines on O/T development (e.g. dealing with overlap, interoperability and alignment between O/Ts, 
avoidance of redundancy and ambiguity, lifecycle management, maintenance, versioning) 
3) Issuing guidelines on O/T deployment (e.g. licensing, documentation, training, software tool support); 
4) Co-ordinating with other bodies that deal with biomedical semantic interoperability (e.g. in the area of EHRs, 
pharmaceutical discovery pipelines (e.g. http://www.pistoiaalliance.org), and clinical biosimulation (e.g. 
http://www.vph-noe.eu); 
5) Conducting independent benchmarking to compare vocabulary products for similar domains;  
6) Supporting efforts towards the (i) alignment of extant O/Ts and (ii) convergence on a single high-quality O/T 
resource for each domain; 
7) Providing scientific advice to specific O/T development consortia, and establish objective criteria (e.g. tangible 
interoperability benefits) for the product quality certification of a vocabulary for a specific domain indication;  
8) Establishing an open semantic interoperability standard development process that defines the minimum 
ontological properties required to represent a particular biomedical domain and involve appropriate scientific, 
software engineering, clinical and industry stakeholders; 
9) Studying the economics of O/T demand and supply, and the key causes that interfere with (i) O/T adoption or (ii) 
the realization of the interoperability benefits following adoption. 
10) Assisting with the global dissemination, adoption and community engagement of both standards and vocabularies. 
11) Supporting the development and use of structured reporting at source (e.g. archetypes and clinical data structures 
for clinical records), as a way to provide a timely and well defined context to O/T terms used during the annotation 
process; 
12) Involving the WHO and national e-health agencies in establishing a communal understanding of the semantic 
interoperability problem and promoting community-wide standardization of thoroughly tested and technically 
coherent methods. 
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